The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …

Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

The approach to the patient with relapsed or relapsed/refractory multiple myeloma (RRMM)
requires a careful evaluation of the results of previous treatments, the toxicities associated …

Involvement of the central nervous system (CNS) in multiple myeloma (MM) is a rare
complication, with reported survival of< 6 months. This report describes 37 MM patients with …

Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …

Major progress has been made in the upfront treatment of multiple myeloma, but the disease
ultimately relapses and leads to death in the vast majority of those afflicted. New treatment …

Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM)
using VDT PACE regimen and its modifications (VDT PACE‐like regimens: VPLRs) outside …

Belantamab mafodotin (belamaf) is a first-in-class anti-B-cell maturation antigen (BCMA)
antibody–drug conjugate (ADC) that recently gained regulatory approval for the treatment of …

Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly
diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind to cereblon …